(SEOUL, South Korea) – Intelsius, a global designer, manufacturer and distributor of temperature-controlled and regulatory-compliant packaging solutions, announced a partnership with BioCore in South Korea. In line with the company’s international growth strategy, the partnership with BioCore aligns the growing global presence of Intelsius and its core strategy of offering products globally with local supply.
“South Korea is an important strategic opportunity for Intelsius, our partnership with BioCore as the exclusive distributor of our solutions will allow us to better ensure patient safety in this growing pharma market,” said David Walsh, CEO of Intelsius. “The partnership enables Intelsius to meet the increasing demand for temperature control and regulatory-compliant packaging systems for the life science sector in this region.”
“There are more clinical trials going on in South Korea than in any other country in East Asia estimated at more than 3,100,” said Hyung-Sik Choie, president and CEO of BioCore. “Our partnership with Intelsius will have an immediate impact on the accuracy of those trials and more importantly, it will enhance the safety of the patients participating. “
Experts predict that the growth in cold chain spending over the next three years will be highest in Asia according to the Cold-Chain Biopharma Logistics Sourcebook 2011.
Incorporated in 1998, Intelsius is a subsidiary of DGP Life Science Ltd, which is headquartered in York, United Kingdom. With a strong focus on developing environmentally sustainable products and procedures, the company offers solutions to ensure the integrity of customers’ products and samples for better human and animal health worldwide. Intelsius serves a wide range of organizations, including government agencies, leading pharmaceutical, biopharmaceutical and clinical research industries to major laboratories. Intelsius has manufacturing facilities, distribution hubs and local offices situated throughout the world, including North America, Europe and Asia. For more information, visit www.intelsius.com.
BioCore was established in 2001 as a spin-off from Seoul Clinical Laboratories, the largest reference laboratory in Korea since 1983. The drug development support service division (Bio-analysis, eg. PK and PD-Study) is one of BioCore’s specialized research organizations which utilizes advanced equipment, accumulated analytical ability and more accurate and reliable data complying with GLP standards. BioCore has the first GLP certification in Korea in the field of toxicokinetics analysis by the KFDA.
Tammy Moran (Intelsius) – +1 317 536 9950 or email@example.com